OOIR: Observatory of International Research

Papers

(The TQCC of Lupus Science & Medicine is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Evaluation and randomised controlled trial of home urinalysis testing in patients with SLE at elevated risk for developing lupus nephritis: a study protocol	49
SLESIS-R: an improved score for prediction of serious infection in patients with systemic lupus erythematosus based on the RELESSER prospective cohort	44
Validation of proposals for definitions of moderate and severe disease activity in SLE: impact on flares, quality of life, damage accrual, hospitalisations and mortality	43
Combining mepacrine with hydroxychloroquine-based therapy in active systemic lupus erythematosus: an observational study of 106 patients from the Lupus-Cruces cohort	37
Towards a minimal core dataset for systemic lupus erythematosus studies	35
B lymphocytes in treatment-naive paediatric patients with lupus are epigenetically distinct from healthy children	33
Autoantibody-based subgroups and longitudinal seroconversion in juvenile-onset systemic lupus erythematosus	32
Genetic load in incomplete lupus erythematosus	26
Differences in reproductive health discussions in an urban Hispanic population with SLE: lessons from the field	26
Intermittent and Persistent Type 2 lupus: patient perspectives on two distinct patterns of Type 2 SLE symptoms	25
Novel multiclass classification machine learning approach for the early-stage classification of systemic autoimmune rheumatic diseases	25
Mezagitamab in systemic lupus erythematosus: clinical and mechanistic findings of CD38 inhibition in an autoimmune disease	24
Safety, immunological effects and clinical response in a phase I trial of umbilical cord mesenchymal stromal cells in patients with treatment refractory SLE	24
High-dimensional analysis of T-cell profiling variations following belimumab treatment in systemic lupus erythematosus	23
Therapy with direct oral anticoagulants for secondary prevention of thromboembolic events in the antiphospholipid syndrome: a systematic review and meta-analysis of randomised trials	22
Langerhans cells infiltration in lymph nodes of patients with systemic lupus erythematosus	22
Generation of evidence supporting the content validity of SF-36, FACIT-F, and LupusQoL, and novel patient-reported symptom items for use in patients with systemic lupus erythematosus (SLE) and SLE wit	21
Retinal toxicity in a multinational inception cohort of patients with systemic lupus on hydroxychloroquine	21
Novel immunoprofiling method for diagnosing SLE and evaluating therapeutic response	21
VPS13C and STING expression in neuropsychiatric systemic lupus erythematosus: unveiling an unbreached territory	20
A better self-efficacy is predictive of better health-related quality of life (HRQoL) in patients with systemic lupus erythematosus: data from the Almenara Lupus Cohort	20
Mesenchymal stem cells improve ovarian function by suppressing fibrosis through CTGF/FAK signalling in systemic lupus erythematosus	19
Disease activity trajectories in paediatric lupus and associations with socioeconomic factors and patient-reported pain	19
Add-on sirolimus for the treatment of mild or moderate systemic lupus erythematosus via T lymphocyte subsets balance	19
Renal response status to predict long-term renal survival in patients with lupus nephritis: results from the Toronto Lupus Cohort	19

B cell polygenic risk scores associate with anti-dsDNA antibodies and nephritis in systemic lupus erythematosus	18
Statin therapy in systemic lupus erythematosus: a meta-analysis of disease activity and inflammatory biomarkers	18
Cortical changes in women with systemic lupus erythematosus with mild cognitive impairment: a voxel-based morphometry and surface-based morphometry study	17
Prediction model for renal outcomes in Latin American Mestizo patients with pure proliferative lupus nephritis	17
Large overlap in neutrophil transcriptome between lupus and COVID-19 with limited lupus-specific gene expression	17
Anti-CD20 alone as maintenance immunosuppressive therapy in severe lupus nephritis: a promising experience that needs to be evaluated	17
Deucravacitinib, an oral, selective, allosteric, tyrosine kinase 2 inhibitor, in patients with active SLE: efficacy on patient-reported outcomes in a phase II randomised trial	17
Impaired regulatory function of granzyme B-producing B cells against T cell inflammatory responses in lupus mice	17
Frequency-dependent and temporal variability of low-frequency fluctuations in patients with primary Sjögren’s syndrome	16
Racial differences in clinical trial perceptions among a large, predominantly Black cohort of people with systemic lupus erythematosus in the Southeastern USA	16
Investigation of the performance of validated cardiovascular risk scores in a global (UK/US) cohort of young people with childhood-onset systemic lupus erythematosus	16
Clarifying misbeliefs about hydroxychloroquine (HCQ): developing the HCQ benefits versus harm decision aid (HCQ-SAFE) per low health literacy standards	16
Comorbid psoriasis in systemic lupus erythematosus: a cohort study from a tertiary referral centre and the National Patient Register in Sweden	15
Long-term efficacy and safety of the Lupus-Cruces Nephritis protocol: a propensity score study of the Lupus-Cruces and Lupus-Bordeaux cohorts	15
Comorbidity clusters and their relationship with severity and outcomes of index diseases, in a large multicentre systemic lupus erythematosus cohort	15
Prevalence and determinants of vertebral fractures in a SLE cohort	15
Clinical features of Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuritis associated with SLE	15
Function of follicular helper 17 T cells in driving B cells for anti-DNA autoantibody production in patients with SLE	15
Neutrophil gelatinase-associated lipocalin (NGAL) in lupus nephritis and beyond	14
Autoimmune encephalitis associated with anti-LGI1 antibody: a potential cause of neuropsychiatric systemic lupus erythematosus	14
Canadian patient experiences of lupus nephritis: a qualitative analysis	14
Clinical and immunological differences between primary and autoimmune-associated neuromyelitis optica spectrum disorders: a retrospective study	14
Item-specific factors associated with damage accrual in systemic lupus erythematosus: insights from a multiethnic, multinational Latin American cohort	14
Genotype-guided new approach for dose optimisation of hydroxychloroquine administration in Chinese patients with SLE	14
Prevalence and predictive factors associated with sustained remission in SLE: a systematic review	13
Rare and common single nucleotide variants in childhood-onset systemic lupus erythematosus	13
Systematic review of the reporting of extrarenal manifestations in observational studies of Saudi patients with systemic lupus erythematosus	13
Cardiovascular risk factors and complications in patients with systemic lupus erythematosus with and without nephritis: a systematic review and meta-analysis	13
Lupus nephritis randomised controlled trials: evidence gaps and under-represented groups	13
Autoantibodies associated with systemic sclerosis in three autoimmune diseases imprinted by type I interferon gene dysregulation: a comparison across SLE, primary Sjögren’s syndrome and systemic scler	13
Dyspigmentation and scarring in cutaneous lupus erythematosus	12
Glucocorticoid tapering early in the course of juvenile SLE: association with lupus low disease activity state and outcomes	12
Patient and healthcare team recommended medication adherence strategies for hydroxychloroquine: results of a qualitative study informing intervention development	12
Meeting report: patient and caregiver recommendations for a mobile health application for paediatric systemic lupus erythematosus	12
Metabolic profiles of cutaneous lupus have abnormalities in the nicotinamide adenine dinucleotide pathway	12
Altered hippocampal connectivity dynamics predicts memory performance in neuropsychiatric lupus: a resting-state fMRI study using cross-recurrence quantification analysis	12
Evaluation of the LFA-REAL clinician-reported outcome (ClinRO) and patient-reported outcome (PRO): prespecified analysis of the phase III ustekinumab trial in patients with SLE	11
Potential causal effect of SLE on osteoporosis, and the mediation effect: a Mendelian randomisation study	11
Lupus spectrum ambiguity has long-term negative implications for patients	11
Association between disease duration and comorbidity burden in systemic lupus erythematosus: a multicentre study from Pakistan	11
Evaluation of the effects of pre-exposure treatment with hydroxychloroquine on the risk of COVID-19 infection and on the efficacy of anti-COVID-19 vaccination during lupus or Gougerot-Sjögren’s diseas	11
Improving patient pathways for systemic lupus erythematosus: a multistakeholder pathway optimisation study	11
Anti-ribosomal-P protein antibodies and systemic lupus erythematosus (SLE): in a cross-sectional study of Danish adult patients with SLE, no significant association is found between anti-ribosomal-P a	11
Discrepant anti-dsDNA testing between EliA and Crithidia in ANA negative samples: just a false positive?	11
Unravelling the TCRβ repertoire: a key to unlocking the immunopathogenesis and precision medicine in SLE	11
Treatment trends of systemic lupus erythematosus from 2007 to 2023 in the USA	11
Unmet needs and challenges in the diagnosis and management of antiphospholipid syndrome: a qualitative stakeholder study within the ReCONNET framework	10
Genetic relationships between systemic lupus erythematosus and a positive antinuclear antibody test in the absence of autoimmune disease	10
Changes in the incidence and prevalence of systemic lupus erythematosus between 1990 and 2020: an observational study using the Clinical Practice Research Datalink (CPRD)	10
Sites of skin inflammation recurrence in patients with SLE: an analysis of clinical trial data	10

Comparison of short interval and low dose (SILD) with high dose of cyclophosphamide in the susceptibility to infection in SLE: a multicentrereal-world study	10
Risks of mortality and severe coronavirus disease 19 (COVID-19) outcomes in patients with or without systemic lupus erythematosus	10
Enhancing lupus outcomes by means of biology beyond overt clinical features, exemplified in an in-depth investigation of the effects of circadian rhythm disruption	10
Conditions identified by common comprehensive geriatric assessment measures and subsequent acute care among adults with SLE	10
Vitamin D level in patients with systemic lupus erythematosus: its relationship to disease course and bone mineral density	10
Positive psychosocial factors may protect against perceived stress in people with systemic lupus erythematosus with and without trauma history	9
Immune complex–driven neutrophil activation and BAFF release: a link to B cell responses in SLE	9
Visceral fat, cardiovascular risk factors and quality of life in lupus activity categorised via complement C3	9
Successful autologous CD19 CAR T cell therapy following severe lupus flare during immunosuppressive washout in refractory lupus nephritis	9
Pregnancy outcomes in antiphospholipid antibody positive patients: prospective results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinica	9
Levels of physical activity in a large international cohort of patients with systemic lupus erythematosus	9
Development and psychometric evaluation of a physician global assessment for type 2 systemic lupus erythematosus symptoms	9
Elevated serum neurofilament light chain levels in patients with neuropsychiatric systemic lupus erythematosus: a cross-sectional study	9
HNF-1β alleviates podocyte injury in lupus nephritis by maintaining endoplasmic reticulum homeostasis	9
Curcumin attenuates lupus nephritis by inhibiting neutrophil migration via PI3K/AKT/NF-κB signalling pathway	8
Proteomics uncovers ICAM2 (CD102) as a novel serum biomarker of proliferative lupus nephritis	8
Predictors of treatment response in a lupus nephritis population: lessons from the Aspreva Lupus Management Study (ALMS) trial	8
Impact of antiphospholipid antibodies on heart valve involvements in systemic lupus erythematosus: based on CSTAR cohort	8
Factors influencing therapeutic efficacy of denosumab against osteoporosis in systemic lupus erythematosus	8
Higher mortality risk from gynaecological neoplasms and non-Hodgkin’s lymphoma in patients with systemic lupus erythematosus: an observational study from the Spanish National Registry	8
Evaluating disease control following belimumab treatment in patients with SLE enrolled in the US OBSErve study	8
Evaluation of RNase therapy in systemic lupus erythematosus: a randomised phase 2a clinical trial of RSLV-132	8
Adverse pregnancy outcomes in women with systemic lupus erythematosus: can we improve predictions with machine learning?	8
Pharmacokinetics, effectiveness, tolerability and effect on quality of life of open-label tofacitinib for the treatment of moderately active mucocutaneous manifestations of SLE: results of a 76-week p	8
Medium-term impact of the SARS-CoV-2 mRNA vaccine against disease activity in patients with systemic lupus erythematosus	8
Validation of eight endotypes of lupus based on whole-blood RNA profiles	8
Mer-tyrosine kinase: a novel susceptibility gene for SLE related end-stage renal disease	8
Elevated serum brain injury markers are associated with disease activity, pro-inflammatory cytokine levels and cognitive dysfunction in adolescents with childhood-onset SLE	8
Dietary Intervention for Systemic Lupus Erythematosus patients based on HLA-DQ2 and DQ8 genotyping (DISH): a protocol for a randomised controlled study	8
Topological structural characteristics in patients with systemic lupus erythematosus with and without neuropsychiatric symptoms	8
Association of disease-modifying antirheumatic drug selection with hospitalised infection among youth with childhood-onset systemic lupus erythematosus	7
Prediction of mortality risk in critically ill patients with systemic lupus erythematosus: a machine learning approach using the MIMIC-IV database	7
Systemic lupus erythematosus comorbid with chronic spontaneous urticaria: a multicentre retrospective study	7
Serum S100A8 as a potential biomarker for diagnosis of antiphospholipid syndrome and risk stratification among aPL carriers	7
Fracture risk tools performance and potential use in systemic lupus erythematosus	7
Assessing grey matter structural alterations in systemic lupus erythematosus using synthetic MRI	7
Impact of low-dose acetylsalicylic acid on pregnancy outcome in systemic lupus erythematosus: results from a multicentre study	7
Clinical outcome in patients with suspected inflammatory neuropsychiatric lupus treated with immunosuppression: an observational cohort study	7
Clinical utility and performance of anti-C1q antibodies for SLE: comparative analysis of three different assays	7
Identification and functional characterisation of a novel DNASE1L3 variant (c.572A>G, p.Asn191Ser) in three Emirati families with systemic lupus erythematosus and hypocomplementaemic urticarial vas	7
Proteins upregulated in thrombotic antiphospholipid syndrome linked to platelet function in contrast with non-antiphospholipid-related thrombosis: insights from two systematic reviews	7
Health information use by patients with systemic lupus erythematosus (SLE) pre and during the COVID-19 pandemic	7
Social Factors, Epigenomics and Lupus in African American Women (SELA) Study: protocol for an observational mechanistic study examining the interplay of multiple individual and social factors on lupus	7
Relationship between retinal microvascular impairment and subclinical atherosclerosis in SLE	7
HDAC3 knockdown inhibits ferroptosis via upregulating Nrf2 to alleviate renal interstitial fibrosis in lupus nephritis	7
Disease-modifying therapies in systemic lupus erythematosus for extrarenal manifestations	7
Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial	7
Baseline characteristics of patients with SLE with and without lupus nephritis from the Latin American multiethnic GLADEL 2.0 cohort	7
Safety and efficacy of belimumab in older adults with SLE: results of an integrated analysis of clinical trial data	7
Learning from serum markers reflecting endothelial activation: longitudinal data in childhood-onset systemic lupus erythematosus	7
Phenotypically driven subgroups of primary antiphospholipid syndrome-associated thrombocytopenia display distinct outcomes: a prospective cohort study with cluster analysis	7
Outcome clusters and their stability over 1 year in patients with SLE: self-reported and performance-based cognitive function, disease activity, mood and health-related quality of life	7